1. Introduction {#s0005}
===============

Epilepsy is one of the most frequent neurological disorders affecting 0.5--1% of the population worldwide. In epilepsy there is an enduring predisposition of the brain to generate seizures ([@b0135]). Despite the introduction of multiple newer antiepileptic drugs (AEDs) over the past 20 years, about 30% of patients with epilepsy become refractory to current treatments or experience significant adverse events ([@b0115; @b0050; @b0120]). Therefore, attempts to identify novel drug therapies that reduce the seizure frequency and improves patient's behavioural life are on. Lacosamide is one of the newer AEDs which promises to be effective and has a better tolerability profile.

Based on experimental evidence it was suggested that lacosamide has a novel mechanism of action: increase of the slow inactivation of the voltage-gated sodium channels ([@b0055; @b0145; @b0025; @b0130]). A pharmacokinetic-pharmacodynamics (efficacy) analysis was performed based on the pooled data from the 3 efficacy trials for partial-onset seizures. Lacosamide exposure was correlated with the reduction in seizure frequency ([@b0130]). Lacosamide showed favourable pharmacokinetics properties, has a low potential for drug--drug interactions and is thus well suited for polytherapy and probably for use in children ([@b0020]). Few studies in adults proved that the proportion of patients with at least a 50% reduction in seizure frequency (50% responder rate) with lacosamide 400 and 600 mg/day were statistically significant ([@b0005]). Though it is not approved for use in children, it may have an active role in the management of paediatric epilepsy because focal seizures are the most common seizure type in children ([@b0010]). From the past 3 years, 7 published studies have reported similar efficacy and safety of lacosamide as an adjunctive treatment in infants, children and young adults with refractory epilepsy ([@b0095; @b0060; @b0085; @b0035; @b0070; @b0080; @b0090; @b0125; @b0065; @b0075; @b0110]). There have been some reports of hyperactivity with lacosamide in children. We wanted to study the safety of lacosamide in children with refractory partial epilepsy. It is a part of our likely upcoming study on effect and tolerability of lacosamide in children with refractory partial epilepsy.

2. Materials and methods {#s0010}
========================

2.1. Patients {#s0015}
-------------

In this prospective study, out of 531 screened patients, 79 patients were enrolled after they fulfilled the inclusion and exclusion criteria. Informed written consent was taken from the parents and approval from the child obtained whereever applicable.

2.2. Study design {#s0020}
-----------------

This, open-label study was conducted over a 30 month duration, after obtaining approval from Institutional Human Ethics Committee.

2.3. Inclusion and exclusion criteria {#s0025}
-------------------------------------

Patients were enrolled based on inclusion criteria of age between 5 and 15 years and those who have had at least 3 month duration of uncontrolled focal epilepsy even after use of 1--4 AEDs. One month before enrolment patients were to have at least 2 seizures. Patients were excluded from the study if they had an underlying metabolic and systemic disorder and if they were diagnosed with pseudo seizures and if they had a progressive neurological disorder. Patients with history of noncompliance and use of investigational drug within 1 month prior to the study were also excluded from the study.

Lacosamide was added to a stable regime of baseline AEDs were administered orally in the form of tablets at a dose of 25 mg twice a day for one week followed by 50 mg twice a day for the remaining period. During the study period, patients were asked to report or call principal investigator (PI) if they developed any complaint or reaction.

2.4. Study assessments {#s0030}
----------------------

Diagnosis of epileptic seizures and syndromes was based on Classification of Epileptic Seizures (Commission on Classification and Terminology of the International League against Epilepsy, 2011) ([@b0015]). After reviewing the semiology of seizures, electroencephalography (EEG) and magnetic resonance imaging (MRI) findings.

At enrolment, after detailed physical examinations, serum samples were drawn to assess transaminase (SGOT/SGPT) levels and an ECG was recorded. Later patients entered into a 3-month maintenance period and two follow up visits of one month interval. Electrocardiogram (ECG) and transaminase levels were estimated at the end of 3 months of maintenance period. No change in the dose of lacosamide was permitted during the maintenance period.

The efficacy measures were analysed based on change in seizure frequency per 28 days. Children experiencing ⩾50% or greater reduction in seizure frequency from baseline to maintenance period and also patients who were seizure free were noted.

The assessment of safety and tolerability was performed at every visit and it consisted of collecting data on adverse events reported by the patient or their caregiver or those observed by the investigator. Patients who were unable to tolerate protocol medication and those experiencing adverse effects were allowed to discontinue treatment. In our study, we measured tolerability based on global five point scale (A score of 5 was given when there was decrease in side effects; a score of 4 when there were no new side effects; score of 3 when there was one new side effect; score of 2 when there were 2--3 side effects and a score of 1, when there were \>3 side effects.).

At the same time, parents or their patients were made to complete 25 items of Connor's CBRS clinical index scale. A high score on an item indicates difficulty in that area of the patient's life. The total score can range from 10 indicating good behaviour to 75 indicating low quality behavioural life.

Caretakers were provided with diary cards, which captured the details of seizures per month, medications taken in the morning and evening, from the beginning of titration period till last evaluation.

2.5. Statistical analysis {#s0035}
-------------------------

Tolerability and effect of lacosamide on the children's behaviour outcome measured using SPSS 20.0 for Windows (IBM Corporation, Armonk, NY, USA) were used for the statistical analysis. Continuous clinical variables were analysed using Wilcoxon signed rank test. The response to lacosamide treatment in improving children's behaviour was analysed using repeated measure ANOVA. Statistical significance was set at *p* \< 0.05.

3. Results {#s0040}
==========

3.1. Demographics data and patient characteristics {#s0045}
--------------------------------------------------

Out of 531 screened patients, 79 patients were enrolled after they fulfilled the inclusion and exclusion criteria. Seventy-six (96.2%) patients completed 3 months of maintenance period. Three patients discontinued due to adverse events. The disposition of patients is summarized in [Table 1](#t0005){ref-type="table"}.

The clinical characteristics of 79 patients with refractory partial epilepsy are presented in [Table 2](#t0010){ref-type="table"}. In this study, 53 (69.7%) children were males and 23 (30.2%) were females with a mean age of 8.84 ± 3.09 years (age range 5--15 years). Mean age at seizure onset in males was 6.46 ± 3.57 years and in female, 6.38 ± 3.39 years. Out of 76, 49 (62.02%) children continued lacosamide even after the completion of treatment period while 27 (35.5%) children stopped it after treatment period.

Out of 79 enrolled patients, 3 patients were dropped from the study. The behavioural life of the remaining 76 patients was assessed using 25 item questionnaire that was filled by parents/care takers/attenders. Mean total score at baseline was 48.04 ± 10.57; after 3 months of maintenance period, mean behavioural life was 19.27 ± 08.03 and subsequent follow up visit was 19.05 ± 05.29 as shown in [Fig. 1](#f0005){ref-type="fig"}. Thus scores improved significantly with treatment (ANOVA test with *P* \< 0.001). Thus behavioural scores remained relatively constant from baseline to treatment period to all subsequent follow up visits.

3.2. Efficacy {#s0050}
-------------

At the end of the study (EOS), 76 patients entered the maintenance period with a mean reduction in seizure frequency per 28 days from 13.35 ± 24.12 at baseline to 4.53 ± 13.23 at the EOS (Wilcoxon signed ranked test *p* \< 0.001). At the end of the follow up period, mean reduction in seizure was 3.9 ± 11.81 as shown in [Table 3](#t0015){ref-type="table"}.

3.3. Adverse effects {#s0055}
--------------------

All enrolled patients were included in the safety analysis, which included study of adverse events, laboratory test results and vital signs. Out of 79 patients, 40 (50.63%) experienced side effects.

The common adverse events were hyperactivity, ataxia, drowsiness, insomnia, weight gain, nausea, abdominal discomfort, giddiness, headache, and vomiting as shown in [Fig. 2](#f0010){ref-type="fig"}. Most of the reported side effects were mild to moderate in intensity and did not need discontinuation of treatment. Overall results of clinical laboratory tests as well as periodic physical examinations, neurological examinations and assessments of vital signs did not reveal any changes with lacosamide treatment.

Lacosamide was withdrawn in three patients (3.79%). Reasons for discontinuation were unsatisfactory seizure control (one patient) and adverse events during the titration and treatment period (one patient with aggressive behaviour and one with vomiting).

4. Discussion {#s0060}
=============

This prospective, open label treatment study demonstrates that adjunctive therapy with oral lacosamide in children with uncontrolled epilepsy, not only reduces seizure frequency with better tolerability profile, there is improvement in children's behaviour and it causes fewer side effects. The study confirms the clinical efficacy and tolerability of lacosamide in refractory epilepsy in children and validates findings from previous studies.

In a multicentre prospective study by Verrotti et al. that compared lacosamide in paediatrics and adults, a total of 118 patients (59 group A, 59 group B) with uncontrolled generalized and focal epilepsy were enrolled. At 3-month evaluation, 118 treated patients and 56 subjects (47.4% group A; 47.4% group B; *p* = 0.8537) experienced at least 50% reduction in seizure frequency respectively ([@b0130]).

In randomized controlled trials conducted in adults, lacosamide has been shown to be an effective and safe AED in treating refractory seizures, with 30--40% of patients achieving a ⩾50% reduction in seizure frequency at doses of 400--600 mg/day ([@b0060; @b0085; @b0035; @b0015; @b0040]).

In the last 3 years, 7 published studies have reported similar efficacy and safety of lacosamide in infants, children and young adults with refractory epilepsy that had shown greater reduction in seizure frequency and few children with seizure free status ([@b0070; @b0080; @b0090; @b0125; @b0065; @b0075; @b0110]).

Lacosamide has been reported to be a well-tolerated and relatively safe drug ([@b0030]). Mild adverse reactions, such as dizziness, headache, diplopia, nausea and somnolence, drowsiness, dizziness have been observed in paediatric case reports and case series ([@b0080; @b0090; @b0065; @b0030]). The most common adverse event observed in our study (50.63%) was almost congruent with those reported by [@b0070] Adverse effects seen with lacosamide in adults are dose-related ([@b0030]) and same was seen in paediatrics. Many of them are reversible upon discontinuation or dose reduction.

The effect of lacosamide on behaviour in 76 patients was measured using mean scores. The behavioural scores improved significantly with treatment (ANOVA test with *P* \< 0.001) using Conner's Comprehensive Behavior Rating Scales ([@b0045]). The scores remained relatively constant from baseline to treatment period to all subsequent follow up visits. The possible reasons for a favourable effect of lacosamide on behavioural scores could be attributed to improved adherence of children to twice-daily dose of LCM leading to better seizure control and that in turn helped to sustain behavioural improvements.

In our study population, lacosamide showed greater efficacy and was well tolerated with no relationship between dose and adverse effects development. Most adverse effects seen with lacosamide in adults are dose-related and are reversible upon discontinuation or dose reduction ([@b0075]). One of the literature stated that patient who received the highest lacosamide dose (20 mg/kg/day) did not experience any adverse effects ([@b0030; @b0140]). Plasma drug levels were not determined in our study. The literature suggests that adverse effects associated with lacosamide therapy are generally mild-to-moderate in severity.

Lacosamide was discontinued in one patient (1.26%) because of severe hyperactivity, aggression and inattention for one week after starting the drug. These symptoms persisted for one month till the drug was continued and the behavioural symptoms reverted back to normal status after the drug was stopped ([@b0100; @b0105]). Two (2.53%) others withdrew from study due to vomiting and instability in seizure control respectively.

5. Conclusions {#s0065}
==============

In conclusion, lacosamide is one of the newest additions to the AED category and represents a possible option, currently available for refractory partial epilepsy. To the best of our knowledge, this is the first prospective study in a large sample of children (\>55 subjects). Results from our prospective, open label, hospital based study confirm the usefulness of LCM for adjuvant treatment in patients with refractory partial epilepsy. Lacosamide showed favourable safety, tolerability profile and improved behavioural life scores with no increase in seizure frequency. A few more multi-centre randomized controlled trials are required to validate our study results.
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###### 

Patient disposition.

  Study details                                             Value
  --------------------------------------------------------- ------------
  No. of patients enrolled                                  79
  No. of patients completed                                 76 (96.2%)
  No of patients completed 3 months of treatment duration   46 (58.2%)
  No. of patients continued even after treatment period     30 (37.9%)
  No. of patients discontinued the study                    03 (3.79%)

###### 

Demographic data and patient characteristics.

  Characteristics                                             Value
  ----------------------------------------------------------- -------------
  Age, year                                                   8.84 ± 3.09
                                                              
  *Sex, n (%)*                                                
  Male (53)                                                   8.93 ± 3.09
  Female (26)                                                 8.65 ± 3.31
                                                              
  *Follow up duration on lacosamide*                          
  Continued                                                   49 (62.02%)
  Discontinued after treatment period                         27 (35.5%)
                                                              
  *Co-administered drugs along with lacosamide (LCM) n (%)*   
  1                                                           38 (48.1%)
  2                                                           35 (44.3%)
  3                                                           05 (6.3%)
  4                                                           00 (0.0%)
  5                                                           01 (1.35%)
                                                              
  *Onset of seizure*                                          
  Males                                                       6.46 ± 3.57
  Females                                                     6.38 ± 3.39
                                                              
  *Duration of seizure*                                       
  \<1 month                                                   20 (25.3%)
  1 month--1 year 15 (19.0%)                                  15 (19.0%)
  1--2 year                                                   15 (19.0%)
  \>3                                                         29 (36.7%)

Co-administered drugs: VPA: valproic acid, CLB: clobazam, CBZ: carbmazepine, OXC: oxcarbamazepine, LMT: lamotrigine, LEV: levetiracetam, TPM: topiramate, PHT: phenytoin, ZNS: zonisamide, PB: phenobarbitone, CNZ: clonazepam, NPM: nitrazepam.

###### 

Diseases and drug characteristics.

  Clinical findings                                               Values          
  --------------------------------------------------------------- --------------- ------------
  *Seizure type*                                                                  
  Temporal lobe epilepsy                                          3 (5.8%)        1 (3.84%)
  Frontal lobe epilepsy                                           13 (25.0%)      7 (26.6%)
  Occipital lobe epilepsy                                         24 (44.2%)      6 (23.0%)
  Centrotemporal epilepsy                                         01 (1.9%)       3 (11.5%)
  Multifocal                                                      06 (11.5%)      9 (34.5%)
  others                                                          06 (11.5%)      0 (0.0%)
                                                                                  
  *Aetiology classification:*                                                     
  Idiopathic/genetic                                              16 (30.8%)      03 (11.5%)
  Structural/metabolic                                            32 (61.5%)      18 (69.1%)
  Cryptogenic/unknown                                             05 (9.6%)       05 (19.0%)
                                                                                  
  *Retention of lacosamide (months)*                                              
  ⩽6                                                              02 (2.5%)       
  7--12                                                           20 (25.3%)      
  13--18                                                          14 (17.7%)      
  19--24                                                          08 (10.1%)      
  \>24                                                            05 (6.3%)       
  Discontinued after treatment period                             30 (38%)        
                                                                                  
  *Connors comprehensive behaviour rating scale*                                  
  Baseline − mean ± SD                                            48.04 ± 10.57   
  End of the study − mean ± SD[⁎](#tblfn2){ref-type="table-fn"}   19.27 ± 08.03   
  Follow up[⁎](#tblfn2){ref-type="table-fn"}                      19.05 ± 05.29   
                                                                                  
  *Seizure frequency per 28 days:*                                                
  Mean ± SD − baseline                                            13.3 ± 24.11    
                                                                                  
  *End of the study seizure frequency:*                                           
  Mean ± SD                                                       4.53 ± 13.22    
  \% Reduction (*p* \< 0.001)[\#](#tblfn1){ref-type="table-fn"}   59.9 ± 99.9     

*p* \< 0.001, showed significant difference using Wilcoxon signed ranks test.

*P* \< 0.001, showed significant difference using ANOVA test.
